This study from the Women's Health Initiative Observational Study examined how postmenopausal hormone therapy (PHT) affects biomarkers associated with coronary heart disease (CHD). Results showed that PHT use is linked to increased CRP, HDL, and triglyceride levels, as well as lower tPA-antigen and homocysteine. Estrogen plus progestin use was associated